1. Those who receiveDrug Semaglutide An average weight loss of 14.9% compared to a 2.4% reduction in those receiving placebo.
2. People receiving semaglutide and changing their lifestyle lost at least 20% (in 1/3 of people taking semaglutide).
Most importantly, it is a study that experimented with youth (teenagers) who are obese (obese), which is the group with the most difficult obesity to lose weight.
In the past, if expecting to lose that much weight would have to rely on surgery and increase the use of older diet pills that have very dangerous side effects on the body
But Semaglutide did not show any serious side effects. It is an adaptation of a diabetes drug that was approved by the U.S. Food and Drug Administration four years earlier (Liraglutide).
The key drug used in the treatment of diabetes (and obesity) is the hormone GLP-1 (Glucagon-like peptide1), which stimulates insulin production. to make sugar out of the blood vessels into the cells which results in reduced blood sugar levels (enhanced insulin production and reduced blood sugar)
The problem is that the drug isn’t cheap at about $1,300 a month. (and most health insurance companies won’t pay for it)
It was also found that when Semaglutide was discontinued and lifestyle changes were discontinued, Body weight of people who have passed the test It will increase to about 2/3 of the amount that has decreased after 1 year.
Some may think that a better solution is Being more disciplined in reducing the amount of food you eat and exercising regularly. But it must be acknowledged that previous research (1990) concluded that “genetic influences on body mass index are substantial, whereas childhood environment had little or no influence.”
The research was published in the journal New England Journal of Medicine By comparing the body weights of twins raised in different environments.
Based on the data, 93 pairs of identical twins raised in different environments. This was compared with 218 pairs of fraternal twins raised in different environments. and compared with 208 pairs of fraternal twins growing up in the same household.
(identical twin is a brother-sister of the same sex with the same genes Because it is a twin pregnancy caused by the fertilization of a single egg with a single sperm. then split into two embryos, while fraternal twins are fraternal twins formed by fertilization between two sets of egg cells and sperm)
However, the US CDC concluded that Obesity is not caused by a fault in one gene. But the research concludes that there may be more than 50 genes that affect obesity risk.
There may be an abnormality in the MC4 R gene that is a key factor in obesity.
My conclusion (personally) is to try as much as possible to keep my weight within the limits. By limiting eating time to no more than exercise time every day (If a day takes 90 minutes to eat, then 90 minutes to exercise as well)
And will not eat dinner to have an empty stomach every day for 12-14 hours a day, with free time spent exercising But it is well understood that obesity is increasing exponentially around the world.
According to WHO data, the number of obese people doubled between 1975 and 2016 (latest data). Approximately 13% of the world’s population is obese. (In Thailand, probably about 10% of the population) and obesity is increasing significantly among young people as well.
So, a new drug to lose weight better than Semaglutide that the market is waiting for the US Food and Drug Administration to approve in 2023 isTirzepatide tablets of Eli Lily, which is also an injectable drug.
Tirzepatide contains a major GLP-1 activator (like Semeglutide) and another GIP (Glucose-dependent insulinotropic polypeptide).
This is strange because in experiments in mice it was found that low GIP levels prevented the mice from becoming obese. But in this case, increasing the GIP allows for further weight reduction.
However, the results of the tirzepatide trial were
1. An average weight reduction of 21% in the high dose compared to a 3% reduction in body weight in the placebo group.
2. Able to reduce body weight by up to 30% within 6 months (using the highest dose).
3. Continuous weight loss after 6 months, can continue for another 1-2 years.
Analysts expect Eli Lily to price Tirzepatide similar to its competitors at $1,300 per month, or a minimum of $1,100 per month.
In this regard, analysts of Bank of America, partner of Kiatnakin Phatra Sales of Tirzepatide are estimated to be at an all-time high of $48 billion per year.
But UBS analysts estimate the network’s lower end at $25,000 a year, which is still the highest on record.
Because the current top-selling drugs are rheumatoid arthritis drugs, with annual sales of $20.5 billion. (I repeat, this information is not a persuasion to buy any particular stock.)